March 27, 2017 1:51 PM ET


Company Overview of Intrexon Corporation

Company Overview

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics platform. It also provides reproductive technologies and other genetic processes to cattle breeders and producers; genetic preservation and clon...

20374 Seneca Meadows Parkway

Germantown, MD 20876

United States

Founded in 1998

832 Employees



Key Executives for Intrexon Corporation

Chairman and Chief Executive Officer
Age: 63
Total Annual Compensation: $4.4M
Chief Financial Officer
Age: 52
Total Annual Compensation: $785.5K
Senior Vice President of Finance
Age: 55
Total Annual Compensation: $315.4K
Chief Communications Officer and Senior Vice President
Age: 50
Total Annual Compensation: $238.7K
Age: 71
Total Annual Compensation: $879.2K
Compensation as of Fiscal Year 2015.

Intrexon Corporation Key Developments

Intrexon Corporation Announces the Formation of Wholly-Owned Subsidiary, Precigen, Inc; Announces Executive Changes

Intrexon Corporation announced the formation of Precigen Inc., a wholly-owned subsidiary of the company as part of an ongoing evaluation of structural alternatives concerning its business in healthcare. Intrexon currently intends to consolidate all health-related assets under this new corporate entity as it considers potential strategic options to enhance shareholder value. Through utilization of Intrexon's proprietary technology platform, gene and cell therapy candidates in an array of therapeutic areas including oncology, rare diseases, infectious diseases, ophthalmology, and cardiovascular disease are under development or have completed development. Precigen will encompass all of Intrexon's health related collaborations, including its Exclusive Channel Collaborations and Research Collaborations, Joint Ventures and its 75% ownership stake in its Xogenex subsidiary. Intrexon also announced that Geno Germano is stepping down as President, and Randal Kirk has cancelled plans to transition to Executive Chairman and will remain Chairman and CEO. Intrexon has a search underway for an executive to lead Precigen.

Intrexon Looking At Strategic Options

Intrexon Corporation (NYSE:XON) currently intends to consolidate all health-related assets under a new corporate entity as it considers potential strategic options to enhance shareholder value. "While we have been reviewing potential options for over a year, as our collaborators increasingly begin to move into the clinic, it is apparent that our collection of health assets may be overshadowed by the breadth and complexity of the opportunities the engineering of biology has afforded us. We are therefore taking this structural action now to better position us for strategic decisions regarding our health business moving forward," said Randal J Kirk, Chairman and Chief Executive Officer. "Notably this structural move will have no impact on the programs of our collaborations in health or the pipeline of clinical stage product candidates."

Intrexon Corporation Announces Appointment of Andy Bass as Senior Vice President, Consumer Sector

Intrexon Corporation announced the appointment of Andy Bass as Senior Vice President, Consumer Sector, which will henceforth do business as BioPop. Andy will lead the design and commercialization of new biologically-based products and applications across consumer markets using Intrexon's powerful platforms and expertise for engineering biology. Andy brings extensive experience in life sciences and consumer product development to Intrexon.  Most recently he co-founded and served as Chief Executive Officer of Biological & Popular Culture Inc. (BioPop), now a wholly owned subsidiary of Intrexon and a consumer biotechnology company selling products in more than 20 countries.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

January 24, 2017
GenVec, Inc.
Private Placement
June 30, 2016
Oragenics, Inc.
Private Placement
June 29, 2016
ZIOPHARM Oncology, Inc.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Intrexon Corporation, please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at